Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

DDK Has a Primary Role in Processing Stalled Replication Forks to Initiate Downstream Checkpoint Signaling.

Sasi NK, Coquel F, Lin YL, MacKeigan JP, Pasero P, Weinreich M.

Neoplasia. 2018 Oct;20(10):985-995. doi: 10.1016/j.neo.2018.08.001. Epub 2018 Aug 26.

2.

DDK Promotes Tumor Chemoresistance and Survival via Multiple Pathways.

Sasi NK, Bhutkar A, Lanning NJ, MacKeigan JP, Weinreich M.

Neoplasia. 2017 May;19(5):439-450. doi: 10.1016/j.neo.2017.03.001. Epub 2017 Apr 25.

3.

The potent Cdc7-Dbf4 (DDK) kinase inhibitor XL413 has limited activity in many cancer cell lines and discovery of potential new DDK inhibitor scaffolds.

Sasi NK, Tiwari K, Soon FF, Bonte D, Wang T, Melcher K, Xu HE, Weinreich M.

PLoS One. 2014 Nov 20;9(11):e113300. doi: 10.1371/journal.pone.0113300. eCollection 2014.

4.

PRKDC mutations in a SCID patient with profound neurological abnormalities.

Woodbine L, Neal JA, Sasi NK, Shimada M, Deem K, Coleman H, Dobyns WB, Ogi T, Meek K, Davies EG, Jeggo PA.

J Clin Invest. 2013 Jul;123(7):2969-80. doi: 10.1172/JCI67349. Epub 2013 Jun 3.

5.

Radiosensitization of cancer cells by hydroxychalcones.

Pruitt R, Sasi N, Freeman ML, Sekhar KR.

Bioorg Med Chem Lett. 2010 Oct 15;20(20):5997-6000. doi: 10.1016/j.bmcl.2010.08.081. Epub 2010 Aug 22.

6.

Novel substituted (Z)-5-((N-benzyl-1H-indol-3-yl)methylene)imidazolidine-2,4-diones and 5-((N-benzyl-1H-indol-3-yl)methylene)pyrimidine-2,4,6(1H,3H,5H)-triones as potent radio-sensitizing agents.

Reddy YT, Sekhar KR, Sasi N, Reddy PN, Freeman ML, Crooks PA.

Bioorg Med Chem Lett. 2010 Jan 15;20(2):600-2. doi: 10.1016/j.bmcl.2009.11.082. Epub 2009 Nov 22.

7.

Regulated cell death pathways: new twists in modulation of BCL2 family function.

Sasi N, Hwang M, Jaboin J, Csiki I, Lu B.

Mol Cancer Ther. 2009 Jun;8(6):1421-9. doi: 10.1158/1535-7163.MCT-08-0895. Epub 2009 Jun 9. Review.

Supplemental Content

Support Center